KDR and cancer: A random-effects model (c2-based Q-statistic test: q = 3727.72; P < 0.001; I2 = 98.3%) revealed that the total occurrence of all-grade hypertensive occasions in cancer patients treated with VEGFR-TKIs was 23.0% (95% CI, 20.1-26.0%, Supplementary Table 4 and Figure S1).